Pancreatic adenocarcinoma

Related records

Broader conditions (23)

• Adenocarcinoma
• Cancer
• Cancer or benign tumor
• Carcinoma
• Digestive system cancer
• Digestive system carcinoma
• Digestive system disorder
• Digestive system neoplasm
• Disease
• Disease by body system or component
• Disease by etiologic mechanism
• Endocrine system disorder
• Epithelial neoplasm
• Exocrine pancreatic carcinoma
• Glandular cell neoplasm
• Human disease
• Malignant exocrine pancreas neoplasm
• Malignant pancreatic neoplasm
• Neoplasm
• Neoplastic disease or syndrome

Narrower conditions (16)

• Colloid carcinoma of the pancreas
• Mixed ductal-endocrine carcinoma of pancreas
• Mucinous pancreas adenocarcinoma
• Pancreatic acinar cell carcinoma
• Pancreatic acinar cell cystadenocarcinoma
• Pancreatic cystadenocarcinoma
• Pancreatic ductal adenocarcinoma
• Pancreatic foamy gland adenocarcinoma
• Pancreatic intraductal papillary-mucinous neoplasm with an associated invasive carcinoma
• Pancreatic mucinous cystadenocarcinoma
• Pancreatic mucinous-cystic neoplasm with an associated invasive carcinoma
• Pancreatic non-invasive mucinous cystadenocarcinoma
• Pancreatic serous cystadenocarcinoma
• Pancreatic signet ring cell adenocarcinoma
• Undifferentiated pancreatic carcinoma
• Undifferentiated pancreatic carcinoma with osteoclast-like giant cells

Trials (605)

• 18F-FAPI PET Imaging in Pancreatic Adenocarcinoma
• 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
• 3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery
• 4D-CT for Pancreatic Adenocarcinoma in Radiotherapy Simulation
• 64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer
• 68Ga-FAPI-46 in Staging of Pancreatic Adenocarcinoma
• 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
• 9-ING-41 in Patients With Advanced Cancers
• 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma
• A Beta-only IL-2 ImmunoTherapY Study
• A Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring
• A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
• A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer
• A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
• A Phase 1 Trial Of Safety And Initial Efficacy Of Vagal Nerve Blockade For Cancer-Induced Cachexia In Patients With Metastatic Pancreatic Adenocarcinoma
• A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
• A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
• A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
• A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer
• A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma

Drugs in development (19)

• Anakinra Phase 2
• Capecitabine Phase 2
• Durvalumab Phase 2
• Erlotinib Phase 2
• Ethiodized oil Phase 1
• Fluorouracil Phase 3
• Gemcitabine Phase 3
• Gemcitabine hydrochloride Phase 2
• Indusatumab vedotin Phase 2
• Irinotecan Phase 3
• Irinotecan hydrochloride Phase 2
• Leucovorin Phase 3
• Levoleucovorin Phase 2
• Nivolumab Phase 2
• Oxaliplatin Phase 2
• Paclitaxel Phase 3
• Pancrelipase Phase 2
• Selicrelumab Phase 1
• Sotorasib Phase 2

Other linked drugs (2)

• Hydroxychloroquine sulfate
• Ramucirumab